PT596. The comparison with galantamine and donepezil on Alzheimer’s Disease patients and its relationship with cerebral blood flow

Abstract

Objective: In this study, we compared the effect of galantamine and donepezil, by investigating the cognitive function, behavioral and psychological symptoms of dementia (BPSD) and the care burden, in patients with Alzheimer’s disease (AD). Furthermore, with Near-Infrared Spectroscopy (NIRS), we examined the association between effect of galantamine and donepezil and brain blood flow.

Methods: Evaluated the effect of galantamine and donepezil from baseline on Clinical Global Impression - Improvement scale (CGI-I), Mini-Mental State Examination (MMSE), Clock Drawing Test (CDT), Neuropsychiatric Inventory (NPI), Japanese version of the Zarit Burden Interview (J-ZBI) and NIRS in two groups, the donepezil group (n=14) and the galantamine group (n=13) were assessed at weeks 0, 4, 12, and 24.

Results: Significant difference was found between the galantamine group and the donepezil group in the score variation of MMSE (12w: p<0.05, 24w: p<0.01), NPI (12w: p<0.05, 24w: p<0.001), and J-ZBI (24w: p<0.001). The NIRS measurement was observed to tend to reduce oxyhemoglobin suppression in CH8 channel centered on the superior frontal gyrus.

Conclusions: In this study, by administering galantamine in AD patients that inhibit the reduction of cerebral blood flow in the prefrontal area and improve clinical symptoms overall, cognitive function, thereby reducing the care burden of caregivers was suggested.